xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

416

International consensus statement on rhinosinusitis

Short-term effect on S. aureus clearance with

Nebulized tobramycin in CF may reduce P. aeruginosa. Higher

(Continues)

required to evaluate efficacy of topical antibiotics

antibiotic compared to saline.

No benefit seen with topical antibiotic.

level studies needed.

mupirocin, but no

effect on long-term outcomes

No benefit seen with topical antibiotic.

Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Mainz 1150 2014 2 DBRCT Patients with CF P. aeruginosa colony count QoL

Additional studies

No benefit of topical

Nasal endoscopy CT

QoL

Symptoms QoL

Nasal endoscopy

Symptoms

Otologic/renal safety

Bacterial culture Symptoms QoL

Symptoms

QoL questionnaire Nasal endoscopy

2. 6 weeks saline rinse (n = 19)

Post-ESS recalcitrant infection with S. aureus 1. Nebulized bacitracin-colimycin + 2

1. 6 weeks saline rinse +

Jervis-Bardy 593 2012 2 DBRCT Post-ESS recalcitrant infection with s. aureus 1. Mupirocin rinses + PO placebo (n = 9) 2. Saline rinses + PO

weeks PO levofloxacin 2. Nebulized saline + 2weeks PO levofloxacin (Total n = 14)

1. Nebulized 80 mg tobramycin 28days (n = 6) 2. Nebulized saline 28 days (n = 3)

gentamicin (80 mg/1000 mL) (n = 21)

2. Saline-quinine nebulization TID for 4 weeks (Total n = 20)

amoxicillin/clavulanate (n = 13)

nebulization TID for 4 weeks

Wei 1158 2011 2 DBRCT Pediatric CRS

Desrosiers 1138 2001 2 DBRCT Post-ESS recalcitrant CRS 1. Tobramycin-saline

heterogeneity

Videler 1137 2008 2 DBRCT cross-over pilot study

Huang 1157 2013 2 Review with

TABLE IX-33 (Continued)